Safety and tolerability of the treatment of youth-onset type 2 diabetes: the TODAY experience

TODAY Study Group, Neil H White, Laura Pyle, Steven M Willi, Trang Pham, Steven D Chernausek, Robin Goland, Naomi Berrie, Daniel E Hale, Morey W Haymond, Kristen J Nadeau, Sumana Narasimhan, TODAY Study Group, Neil H White, Laura Pyle, Steven M Willi, Trang Pham, Steven D Chernausek, Robin Goland, Naomi Berrie, Daniel E Hale, Morey W Haymond, Kristen J Nadeau, Sumana Narasimhan

Abstract

Objective: Data related to the safety and tolerability of treatments for pediatric type 2 diabetes are limited. The TODAY clinical trial assessed severe adverse events (SAEs) and targeted nonsevere adverse events (AEs) before and after treatment failure, which was the primary outcome (PO).

Research design and methods: Obese 10- to 17-year-olds (N = 699) with type 2 diabetes for <2 years and hemoglobin A1c (A1C) ≤ 8% on metformin monotherapy were randomized to one of three treatments: metformin, metformin plus rosiglitazone (M + R), or metformin plus lifestyle program (M + L). Participants were followed for 2-6.5 years.

Results: Gastrointestinal (GI) disturbance was the most common AE (41%) and was lower in the M + R group (P = 0.018). Other common AEs included anemia (20% before PO, 14% after PO), abnormal liver transaminases (16, 15%), excessive weight gain (7, 9%), and psychological events (10, 18%); the AEs were similar across treatments. Permanent medication reductions/discontinuations occurred most often because of abnormal liver transaminases and were lowest in the M + R group (P = 0.005). Treatment-emergent SAEs were uncommon and similar across treatments. Most (98%) were unrelated or unlikely related to the study intervention. There were no deaths and only 18 targeted SAEs (diabetic ketoacidosis, n = 12; severe hypoglycemia, n = 5; lactic acidosis, n = 1). There were 62 pregnancies occurring in 45 participants, and 6 infants had congenital anomalies.

Conclusions: The TODAY study represents extensive experience managing type 2 diabetes in youth and found that the three treatment approaches were generally safe and well tolerated. Adding rosiglitazone to metformin may reduce GI side effects and hepatotoxicity.

Trial registration: ClinicalTrials.gov NCT00081328.

References

    1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA, U.S. Department of health and Human Services, Centers for Disease Control and Prevention. Available from Accessed 18 October 2012
    1. Liese AD, D’Agostino RB, Jr, Hamman RF, et al. SEARCH for Diabetes in Youth Study Group The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics 2006;118:1510–1518
    1. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 2000;136:664–672
    1. Zeitler P, Epstein L, Grey M, et al. TODAY Study Group Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes 2007;8:74–87
    1. Copeland KC, Zeitler P, Geffner M, et al. TODAY Study Group Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab 2011;96:159–167
    1. Zeitler P, Hirst K, Pyle L, et al. TODAY Study Group A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med 2012;366:2247–2256
    1. TODAY Study Group Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study. Int J Obes (Lond) 2010;34:217–226
    1. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28(Suppl. 1):S37–S42
    1. Kahn SE, Zinman B, Lachin JM, et al. Diabetes Outcome Progression Trial (ADOPT) Study Group Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845–851
    1. de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010;340:c2181.
    1. Reinstatler L, Qi YP, Williamson RS, Garn JV, Oakley GP., Jr Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2012;35:327–333
    1. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89–94
    1. DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541–549
    1. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106–1118
    1. Khanolkar MP, Morris RHK, Thomas AW, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008;197:718–724
    1. Kim YM, Cha BS, Kim DJ, et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005;67:43–52
    1. Berberoglu Z, Yazici AC, Bayraktar N, Demirag NG. Rosiglitazone decreases fasting plasma peptide YY3-36 in type 2 diabetic women: a possible role in weight gain? Acta Diabetol 2012;49(Suppl. 1):S115–S122
    1. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256–263
    1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960–967
    1. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics 2006;118:1388–1393
    1. Nadeau KJ, Klingensmith G, Zeitler P. Type 2 diabetes in children is frequently associated with elevated alanine aminotransferase. J Pediatr Gastroenterol Nutr 2005;41:94–98
    1. Wicklow BA, Wittmeier KD, MacIntosh AC, et al. Metabolic consequences of hepatic steatosis in overweight and obese adolescents. Diabetes Care 2012;35:905–910
    1. TODAY Study Group Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY. Diabetes Care 2013;36:1749–1757
    1. Yki-Järvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol 2009;20:477–483
    1. Dart AB, Sellers EA, Martens PJ, Rigatto C, Brownell MD, Dean HJ. High burden of kidney disease in youth-onset type 2 diabetes. Diabetes Care 2012;35:1265–1271
    1. Krakoff J, Lindsay RS, Looker HC, Nelson RG, Hanson RL, Knowler WC. Incidence of retinopathy and nephropathy in youth-onset compared with adult-onset type 2 diabetes. Diabetes Care 2003;26:76–81
    1. Balsells M, García-Patterson A, Gich I, Corcoy R. Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis. J Clin Endocrinol Metab 2009;94:4284–4291
    1. Levitt Katz LE, Swami S, Abraham M, et al. Neuropsychiatric disorders at the presentation of type 2 diabetes mellitus in children. Pediatr Diabetes 2005;6:84–89
    1. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010;170:1191–1201

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere